Introduction
============

Obesity is a major public health concern, associated with high cardiovascular and metabolic risks \[[@b1-apem-2019-24-2-99],[@b2-apem-2019-24-2-99]\] and often leading to premature death in adulthood \[[@b3-apem-2019-24-2-99]\]. Among the metabolic comorbidities, hyperinsulinemia and/or insulin resistance (IR) are of particular interest due to the alarming increase of type 2 diabetes in youth \[[@b4-apem-2019-24-2-99]\].

Acanthosis nigricans (AN) is a dermatological condition consisting of symmetrical hyperpigmentation and thickened skin with a rough, velvety texture. AN is typically asymptomatic, although it can sometimes be pruritic. It may affect any part of the skin, but is most common in regions affected by friction. Common sites therefore include the neck, axilla, elbows, knuckles, knees, groin, and anogenital areas \[[@b5-apem-2019-24-2-99]-[@b7-apem-2019-24-2-99]\]. Although the pathogenesis of AN is not fully known, the underlying mechanism is the interaction between insulin-like growth factor 1 (IGF-1) and IGF binding protein 1 (IGFBP-1), which is associated with high insulin levels. Hyperinsulinemia may inhibit IGFBP-1 synthesis and increase the synthesis of IGF-1 in the liver. The increase in IGF-1 circulating concentrations and IGF-1 receptor activation may trigger dermal fibroblast and epidermal keratinocyte proliferation \[[@b5-apem-2019-24-2-99]-[@b8-apem-2019-24-2-99]\].

During puberty adolescents have hyperinsulinemic physiological status \[[@b9-apem-2019-24-2-99]\]. Even higher levels of insulin are observed among overweight adolescents due to increased adipose tissue, associated with increased plasma free fatty acids and adipokines, which in turn may impair glucose transport activity, resulting in IR. IGF-1 may play an important role in this relationship. IGF-I binds to insulin receptors, stimulating glucose transport in the adipose and muscle tissues, inhibiting hepatic glucose output, and simultaneously suppressing insulin secretion, which may lead to a decrease in blood glucose \[[@b10-apem-2019-24-2-99]\]. However, in the presence of IR and consequent hyperinsulinemia, lower levels of IGFBP-1 may lead to disturbances in glucose homeostasis and possibly to prolonged states of IR. These factors may explain the higher prevalence of AN among overweight adolescents, compared to adults and adolescent peers who are not overweight \[[@b11-apem-2019-24-2-99]\].

In addition, several previous studies have reported higher AN prevalence among Black adolescents, associated with insulin hyper-secretion and IR, compared to their White peers \[[@b12-apem-2019-24-2-99]\]. Although it is not fully understood whether insulin hyper-secretion/IR are associated with genetic, lifestyle, and/or socioeconomic differences \[[@b13-apem-2019-24-2-99]\], there is a consensus that AN is associated with overweight and IR.

Although several authors have suggested that the presence of AN may be used as a clinical marker for hyperinsulinemia and IR in overweight adolescents, there is no consensus whether AN scoring adds value to the clinical estimation of IR \[[@b14-apem-2019-24-2-99],[@b15-apem-2019-24-2-99]\]. Burke\'s scale is the most widespread measure used to score AN \[[@b15-apem-2019-24-2-99]\]. Two different versions of this scale (a short and an extended version) are used inconsistently across studies. In addition to this limitation, most previous studies used unbalanced group sizes for comparisons, which may have biased their conclusions.

The main aim of this study was to assess and score AN, using a short (neck and axilla) and an extended version (neck, axilla, elbows, knuckles and knees) of the scale proposed by Burke at al. \[[@b15-apem-2019-24-2-99]\], and to analyze the predictive power of both versions for the clinical estimation of IR.

Materials and methods
=====================

1. Participants
---------------

For this cross-sectional study, we analyzed data from a sample of overweight adolescents (body mass index \[BMI\] ≥85th percentile) aged between 12 and 18 years old who were undergoing treatment at a pediatric obesity clinic.

A total of 79 adolescents were screened for AN between July 2015 and December 2016. Of these, 67 (84.8%) were scored according to Burke\'s scale \[[@b15-apem-2019-24-2-99]\]. Since unbalanced sample sizes can result in inaccurate statistical outcomes and may influence type I error rates \[[@b16-apem-2019-24-2-99]\], we added independent data for 60 adolescents who attended the clinic during the 18-month period immediately prior to July 2015 to the without-AN group (12, corresponding to 15.2%), for a total of 72 adolescents. Clinical data for these adolescents were collected retrospectively. The recruitment design is presented in [Fig. 1](#f1-apem-2019-24-2-99){ref-type="fig"}.

None of the included participants met the criteria for diabetes, nor did any present with other clinical conditions or report using medication that could promote hyperinsulinemia or AN development.

2. Measurements
---------------

### 1) Anthropometric and body composition assessments

Height was assessed with a height stadiometer (seca 217, seca GmbH & Co. KG, Hamburg, Germany) with the head in the Frankfort plane, without shoes, with the participant\'s back to the stadiometer, and after an expiratory phase. Height was registered to the nearest 0.1 cm.

Body weight and body composition were measured with a bioelectrical impedance scale (InBody 230, InBody, Seoul, Korea) to the nearest 0.1 kg, with the subjects wearing as few clothes as possible, and without shoes or socks. Relative body fat mass (%BFM) and relative skeletal muscle mass (%SMM) were calculated by dividing the total BFM (kg) and SMM (kg) by body weight, respectively.

BMI was calculated by dividing the body weight in kilograms by the square of height in meters \[BMI=weight (kg)/height^2^ (m)\]. The calculation of BMI *z*-score was based on World Health Organization data \[BMI *z*-score=\[(BMI/M(t))L(*t*)-1\]/L(*t*)S(*t*)\].

Waist (WC) and hip circumferences (HipC) were assessed using a flexible anthropometric tape (seca 203). WC was measured at the level of the iliac crest, with the subjects standing and at the end of a regular expiration (Cameron method), and HipC at the maximum protuberance of the buttocks.

### 2) Clinical assessments

Pubertal status was assessed and categorized according to Tanner stages. AN was assessed by the same investigator and scored according to the scale outlined by Burke et al. \[[@b15-apem-2019-24-2-99]\] Two different scores were calculated: AN score 1 and AN score 2. AN score 1 was calculated as the sum of the scores in each of the most prevalent AN locations (i.e., neck, axilla) and texture \[AN score 1= neck score (0--4) + axilla score (0--4) + texture (0--3)\]. AN score 2 was calculated as AN score1, plus the presence (or absence) of AN at the elbows, knuckles, and/or knees \[AN score 2=neck score (0--4) + axilla score (0--4) + texture (0--3) + elbows (0--1) + knuckles (0--1) + knees (0--1)\] ([Supplemental Table 1](#SD1-apem-2019-24-2-99){ref-type="supplementary-material"}).

Resting blood pressure was measured using a digital sphygmomanometer (CAS 9302S, CAS Medical Systems, Branford, CT, USA) in the right arm with an appropriate size cuff, after five minutes of rest in the seated position. The measurement was performed three times and the average of the three measurements was recorded.

Biochemical analysis was performed in the laboratory of Clinical Pathology at the hospital. Blood samples were collected after overnight fasting (12 hours) in the presence of one of the parents/caregivers, and after local application of a topical anesthesia patch (eutectic mixture of local anesthetics, EMLA). Blood glucose levels were determined using the hexokinase method, and insulin was assessed using a chemiluminescence immunoassay technique (ADVIA 2400, Siemens, Newark, DE, USA). IR was derived by the homeostasis model assessment (HOMA-IR) method, as follows: insulin (μUI/mL)×glucose (mg/dL/405). Insulin and HOMA-IR values ≥90th percentile were considered to represent hyperinsulinemia and IR, respectively \[[@b17-apem-2019-24-2-99],[@b18-apem-2019-24-2-99]\]. ([Supplemental Table 2](#SD1-apem-2019-24-2-99){ref-type="supplementary-material"}).

3. Statistical analysis
-----------------------

Data were analyzed using IBM SPSS Statistics ver. 22.0 (IBM Co., Armonk, NY, USA).

Chi-square tests and independent sample t-tests were used to analyze differences between the without-AN and AN groups. Logistic regression analyses were conducted to analyze the influence of AN severity scores on IR and hyperinsulinemia.

A *P*-value of \<0.05 was considered statistically significant and odds values \>1.5 as the minimum acceptable effect size.

Results
=======

Data from 139 overweight adolescents (45.3% girls, 5.2% Black), with a mean age of 14.4 (±1.8) years and mean BMI *z*-score 2.50 (±1.1), were included in the analysis. There was no significant difference in the number of Black adolescents between the AN and without-AN groups (7.5 vs. 2.8%, *P*=0.207).

The neck was the most prevalent AN location (85.1%), followed by the axilla (74.6%), elbows (38.8%), knuckles (23.9%), and knees (20.9%) ([Table 1](#t1-apem-2019-24-2-99){ref-type="table"}). All participants with AN at the elbows, knuckles, and/or knees also had AN at the neck and/or axilla, but not vice-versa (data not shown).

Adolescents with AN (n=67) showed higher levels of insulin (*d*=0.56, *P*=0.003) and HOMA-IR (*d*=0.55, *P*=0.003), and higher prevalence of hyperinsulinemia (70.2% vs. 47.2%, *P*=0.008) and IR (62.7% vs. 38.9%, *P*=0.008), compared to adolescents without AN (n=72) ([Table 1](#t1-apem-2019-24-2-99){ref-type="table"}). In addition, insulin and HOMA-IR levels tended to be higher among adolescents with AN and IR, compared to adolescents without AN but with IR (*d*=0.45, *P*=0.065; *d*=0.44, *P*=0.067) (data not shown).

None of the AN severity scores was able to explain either hyperinsulinemia (*β*=1.10, *P*=0.316; *β*=1.15, *P*=0.251) or IR (*β*=1.07, *P*=0.422; *β*=1.10, *P*=0.374). However, the presence of AN alone predicted hyperinsulinemia and the presence of IR in 7.3% (*β*=2.68, *P*=0.008) and 7.1% (*β*=2.59, *P*=0.009) of subjects, respectively. Adolescents with AN had 2.59 and 2.68 greater odds of having hyperinsulinemia or IR, respectively, compared to those without AN ([Table 2](#t2-apem-2019-24-2-99){ref-type="table"}).

Discussion
==========

A review of the literature suggests that AN is a clinical marker for hyperinsulinemia and IR in overweight adolescents \[[@b19-apem-2019-24-2-99]\]. Although one could expect that more severe AN would be associated with more severe IR, there is no consensus in this regard \[[@b15-apem-2019-24-2-99],[@b20-apem-2019-24-2-99],[@b21-apem-2019-24-2-99]\]. Results indicating the relevance of AN scoring for the prediction of IR severity may be biased by inconsistent application of the scoring system and unbalanced sample sizes. In order to overcome these limitations, we opted to use both versions of the AN scale proposed by Burke et al. \[[@b15-apem-2019-24-2-99]\] and to ensure balanced sample sizes.

Our findings suggest that AN scoring is not useful for the estimation of hyperinsulinemia or IR. However, the presence of AN alone predicted hyperinsulinemia and the presence of IR in 7.3% and 7.1% of subjects, with sensitivities of 66.0% and 63.3%, respectively.

AN is a dermatological condition triggered by high insulin levels, usually as a consequence of IR status \[[@b6-apem-2019-24-2-99]-[@b8-apem-2019-24-2-99]\]. We postulate that AN is an ongoing process sensitive not only to insulin level variation, but also to the duration of IR status. Persistent/chronic high insulin levels may induce dermal fibroblasts and epidermal keratinocyte proliferation, AN development, and increased AN severity/extension. However, high AN severity may occur in the presence of high insulin levels during a shorter time frame of exposure.

About 63% of the adolescents in the AN group exhibited IR. It is possible that the remaining 37% developed IR at a specific point in time, with ulterior reversion, and consequent insulin level normalization, leading to reduction of the AN extent overtime, but not to its complete reversion \[[@b5-apem-2019-24-2-99],[@b6-apem-2019-24-2-99],[@b22-apem-2019-24-2-99],[@b23-apem-2019-24-2-99]\]. On the other hand, the 39% of adolescents without AN with IR could have developed IR more recently, and/or their insulin levels were not high enough to trigger AN development. Indeed, despite IR, adolescents without AN have lower levels of insulin, compared to those with AN.

This balance between time of exposure to high insulin levels and the severity of hyperinsulinemia may explain the non-linear relationship observed between insulin/HOMA-IR and AN severity score. In order to understand this relationship, further longitudinal studies are needed.

Although the difference was not statistically significant, it is interesting to observe that the number of Black adolescents was higher in the AN group, which is in line with the results reported by previous studies \[[@b12-apem-2019-24-2-99]\]. Nevertheless, because the difference in the number of Black adolescents between the AN and without-AN groups was not statistically significant, we hypothesized that the effects on the results were also not significant.

This study has some limitations. One is the cross-sectional design, which does not allow for causal inferences. Another possible limitation is the addition of data from 60 adolescents without AN, which were retrospectively collected. Although this addition may result in bias, the reason for the use of retrospective data was to balance the sample size, to address one of the main concerns of this study. In addition, all retrospective data were collected by the same healthcare professionals.

Despite the acknowledged limitations, the results of this study suggest that the neck and axilla should be routinely assessed for the presence of AN, since it is a noninvasive and cost-effective way to identify asymptomatic overweight adolescents who have or are at risk of developing IR, which can be associated with early development of type 2 diabetes mellitus \[[@b19-apem-2019-24-2-99],[@b24-apem-2019-24-2-99]\].

Since AN may have a strong visual impact, its presence alone may be a strong reason for seeking medical care during adolescence. In addition, due to the psychological distress that it may cause \[[@b25-apem-2019-24-2-99]\], AN can be used as a motivational trigger for lifestyle changes and weight loss, through the enhancement of diet and physical exercise.
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###### 

Clinical characteristics of the participants

  Characteristic                        AN group (n=67)   Without-AN group (n=72)   *P*-value
  ------------------------------------- ----------------- ------------------------- -----------------------------------------------------------
  Sex, girls                            32 (47.8)         31 (43.1)                 0.578^[a)](#tfn1-apem-2019-24-2-99){ref-type="table-fn"}^
  Race, Black                           5 (7.5)           2 (2.8)                   0.207^[a)](#tfn1-apem-2019-24-2-99){ref-type="table-fn"}^
  Age (mo)                              176±19            170±22                    0.117
  Tanner stage                                                                      0.004^[a)](#tfn1-apem-2019-24-2-99){ref-type="table-fn"}^
   I                                    0 (0)             1 (1.4)                   
   II                                   1 (1.5)           14 (19.4)                 
   III                                  12 (17.9)         12 (16.7)                 
   IV                                   17 (25.4)         21 (29.2)                 
   V                                    37 (55.2)         24 (33.3)                 
  BMI *z*-score                         2.51±1.34         2.49±0.87                 0.893
  WC (cm)                               102.4±14.2        99.4±12.8                 0.230
  BFM (%)                               41.2±6.1          40.3±5.6                  0.461
  SMM (%)                               32.4±6.1          33.9±5.5                  0.129
  SBP (mmHg)                            123.1±12.9        119.0±12.6                0.060
  DBP (mmHg)                            62.8±9.5          61.1±10.5                 0.337
  Glycemia (mg/dL)                      84.6±8.2          84.1±6.5                  0.693
  Insulin (μlU/mL)                      26.4±16.3         19.0±10.3                 0.003
  HOMA-IR                               5.59±3.51         4.00±2.29                 0.003
  Total cholesterol (mg/dL)             159.5±27.7        152.8±28.0                0.169
  HDL-C (mg/dL)                         47.2±11.3         50.8±12.7                 0.084
  Triglycerides (mg/dL)                 94.5±55.1         79.0±39.3                 0.064
  Hyperinsulinemia (≥90th percentile)   47 (70.2)         34 (47.2)                 0.008^[a)](#tfn1-apem-2019-24-2-99){ref-type="table-fn"}^
  IR (HOMA-IR ≥90th percentile)         42 (62.7)         28 (38.9)                 0.008^[a)](#tfn1-apem-2019-24-2-99){ref-type="table-fn"}^
  AN neck                               57 (85.1)         \-                        \-
  AN axilla                             50 (74.6)         \-                        \-
  AN elbows                             26 (38.8)         \-                        \-
  AN knuckles                           16 (23.9)         \-                        \-
  AN knees                              14 (20.9)         \-                        \-

Values are presented as number (%) or mean±standard deviation.

BMI, body mass index; WC, waist circumference; BFM, body fat mass; SMM, skeletal muscle mass; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostatic model assessment-insulin resistance; HDL-C, high-density lipoprotein cholesterol; AN, acanthosis nigricans.

Chi-square test.

###### 

Summary of logistic regression analysis for AN e AN severity scores for the prediction of hyperinsulinemia and insulin resistance

                  Hyperinsulinemia   IR                                                                            
  --------------- ------------------ ------- ------ ------- ------- ------- ------- ------- ------ ------- ------- -------
  AN score 1      0.091              0.091   1.10   0.316                   0.065   0.081   1.07   0.422           
  AN score 2      0.141              0.123   1.15   0.251                   0.097   1.09    1.10   0.374           
  AN (presence)   0.987              0.374   2.68   0.008   66.0%   58.0%   0.952   0.362   2.59   0.009   63.3%   60.0%

AN, acanthosis nigricans; IR, insulin resistance; *β*, unstandardized beta; OR, odds ratio; SE, standard error for the unstandardized beta.
